NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended June 30, 2017.
“We continued our forward momentum in the second quarter with the expansion of our clinical programs as well as our team,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome. “Our clinical pipeline now consists of three late-stage product candidates: AXS-02, AXS-05, and AXS-06. We look forward to the remainder of the year as we approach results from our ongoing Phase 3 clinical trials.”
